Prognostic significance of serum osteopontin levels in small cell lung cancer
- PDF / 831,352 Bytes
- 7 Pages / 595.276 x 790.866 pts Page_size
- 8 Downloads / 181 Views
RESEARCH ARTICLE
Open Access
Prognostic significance of serum osteopontin levels in small cell lung cancer Chunhua Xu1,2* , Qi Yuan1,2, Wei Wang1,2, Chuanzhen Chi1,2, Qian Zhang1,2, Li Li1,2, Rusong Yang3* and Yuchao Wang1,2
Abstract Background: Osteopontin (OPN) is closely related to tumor occurrence and metastasis. This study explored the clinical value of serum OPN levels in small cell lung cancer (SCLC) patients. Methods: The ELISA method was used to determine the OPN level of 96 SCLC patients before and after first-line chemotherapy, and compared with 60 healthy controls. Results: The serum OPN level of SCLC patients before treatment was significantly higher than that of the healthy control (P < 0.001). Serum OPN levels were related to disease stage, tumor size, and lymph node metastasis (P = 0.012, 0.034, and 0.037, respectively). Serum OPN level decreased after first-line chemotherapy (P = 0.019), which was related to treatment response (P = 0.011). The serum OPN level was an independent predictor of overall survival. Conclusions: The serum OPN level can be used as a biomarker to predict treatment response and survival of SCLC patients. Keywords: Small cell lung cancer, Osteopontin, Biomarker, Treatment responses, Overall survival
Background Lung cancer is one of the most common tumors in the world. According to the pathological type, it is divided into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), of which SCLC accounts for 13% of the total number of cases [1, 2]. Although SCLC is sensitive to radiotherapy and chemotherapy, most of them are diagnosed at an advanced stage with a poor prognosis [3]. The median survival time of untreated patients is only 2–4 months, and the 5-year overall survival rate is 3–8%. So far, platinum-based and etoposide chemotherapy is still the first-line treatment, but the tumor is prone to relapse and metastasis, and the prognosis is poor [4–6]. Therefore, it is necessary to find new * Correspondence: [email protected]; [email protected] 1 Department of Respiratory Medicine, the Affiliated Brain Hospital of Nanjing Medical University, 215 Guangzhou Road, Nanjing 210029, Jiangsu, China 3 Department of Thoracic Surgery, the Affiliated Brain Hospital of Nanjing Medical University, 215 Guangzhou Road, Nanjing 210029, Jiangsu, China Full list of author information is available at the end of the article
biomarkers, to discover and predict the treatment response early. Osteopontin (OPN) is a phosphorylated glycoprotein that is involved in regulating cell adhesion, migration, and invasion [7, 8]. Previous studies have shown that many tumors, such as pancreatic cancer, colon cancer, and NSCLC, have elevated OPN levels [9–13]. Studies have shown that OPN overexpression is related to tumor progression and poor prognosis [14, 15]. Although many studies have shown that OPN is related to the prognosis of various cancers, the relationship between its expression and the clinicopathological characteristics of SCLC patients is still unclear. Therefore, this study fi
Data Loading...
